Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu ...

After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and ...

The US Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Based on this, the drug regulator has cleared the company to begin enrollment in the vaccines' planned Phase 3 trial. Novavax (NVAX) will be working with the clinical trial investigators and other ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...

(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...

Inc. ("Novavax" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

HERNDON, Va., Nov. 11, 2024 /PRNewswire/ -- The American Society of Appraisers (ASA) announces that Lana Vukovljak is no longer serving as Chief Executive Officer of the Society. ASA is committed to ...

RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.